Generic take-up in the pharmaceutical market following patent expiry

By John Hudson
,
:
1) ;
2) ,
;
3) ()
-
(
, , ). ,
( ,
, , ..).
, .. ,
(
, ,
,
- ).

, .
.
;
. -
( , ), ,
, .
,
(1) (2) (
) . -, ,
, -, ,
( )
.
,
( , ,
) (
, , .. , ,
).
( , , )
. , ..
.
, , ( )
Pt, AGEt
A ( ).

 GAGE, Sp
Pp. , ).
)
]

, , , .
. ,
,
.
,
, Waxman-Hutch Act,
,
,
.
, ,
,
. ,
,
,
.
, , .

, , - :
1) , ;
2) ;
3) ,
.
, ,
.
, , .

. , ,
.

.
, , , -
,
. , ,
, ,
. ,
- 180 .

 , Prozac Eli Lilly.

2 73% .
GlaxoSmithKline (GSK)
. GSK Par -
Paxil.
Apotex, 180-
. , Par 180-
,
. Apotex, ,
. , Apotex
$575 . 180- . $150200 . , .. 60% . ,
Apotex , ,
. GSK 50%
, .
,
0 .

, , . ,
.
.
, ,
. 4 ,
. , ,
, ,
(milky way). ,
, . ,
Beyond Lifecycle Management Optimizing Performance Following Patent Expiry Edward
Tuttle, Andrew Parece, and Anne Hector, 2004 ,
, :

/ (,
, ; ,
)
( , )

, 12
,
, . -
.